Stocks & Investing
Tue, May 21, 2024
[ 12:00 AM ] - WOPRAI
Wed, August 9, 2023
[ 12:00 AM ] - WOPRAI
Thu, August 3, 2023
[ 12:00 AM ] - WOPRAI
Mon, June 26, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, May 25, 2023
[ 12:00 AM ] - WOPRAI
Mon, May 8, 2023
[ 12:00 AM ] - WOPRAI
Fri, March 3, 2023
[ 12:00 AM ] - WOPRAI
Wed, March 1, 2023
[ 12:00 AM ] - WOPRAI
Tue, November 15, 2022
[ 12:00 AM ] - WOPRAI
Tue, October 18, 2022
[ 12:00 AM ] - WOPRAI
Wed, August 10, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, August 8, 2022
[ 12:00 AM ] - WOPRAI
Fri, May 13, 2022
[ 12:00 AM ] - WOPRAI
Wed, November 24, 2021
Fri, July 23, 2021
[ 12:00 AM ] - WOPRAI
Mon, April 26, 2021
[ 12:00 AM ] - WOPRAI
Tue, May 12, 2020
Fri, December 13, 2019
[ 12:00 AM ] - WOPRAI
Wed, August 21, 2019
Thu, December 21, 2017
Tue, October 20, 2015 Mark Breidenbach Maintained (ALLO) at Buy with Decreased Target to $13 on, May 21st, 2024
Mark Breidenbach of Oppenheimer, Maintained "Allogene Therapeutics, Inc." (ALLO) at Buy with Decreased Target from $14 to $13 on, May 21st, 2024.
Mark has made no other calls on ALLO in the last 4 months.
There are 5 other peers that have a rating on ALLO. Out of the 5 peers that are also analyzing ALLO, 1 agrees with Mark's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Benjamin Burnett of "Stifel" Maintained at Hold with Increased Target to $4.6 on, Tuesday, May 14th, 2024
These are the ratings of the 4 analyists that currently disagree with Mark
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $9 on, Thursday, May 16th, 2024
- Asthika Goonewardene of "Truist Securities" Maintained at Strong Buy and Held Target at $17 on, Wednesday, May 15th, 2024
- Luca Issi of "RBC Capital" Reiterated at Buy and Held Target at $10 on, Friday, March 15th, 2024
- Brian Cheng of "JP Morgan" Maintained at Buy with Decreased Target to $8 on, Tuesday, February 27th, 2024
